RALLYBIO CORP (RLYB)
US75120L1008 - Common Stock
Taking everything into account, RLYB scores 2 out of 10 in our fundamental rating. RLYB was compared to 568 industry peers in the Biotechnology industry. RLYB has a great financial health rating, but its profitability evaluates not so good. RLYB is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
RLYB had negative earnings in the past year.
In the past year RLYB has reported a negative cash flow from operations.
RLYB had negative earnings in each of the past 5 years.
RLYB had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
RLYB's Return On Assets of -84.77% is on the low side compared to the rest of the industry. RLYB is outperformed by 71.50% of its industry peers.
RLYB has a Return On Equity of -94.57%. This is comparable to the rest of the industry: RLYB outperforms 47.61% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -84.77% | ||
| ROE | -94.57% | ||
| ROIC | N/A |
ROA(3y)-42.41%
ROA(5y)-45.43%
ROE(3y)-45.45%
ROE(5y)-51.94%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
RLYB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
Compared to 1 year ago, RLYB has about the same amount of shares outstanding.
There is no outstanding debt for RLYB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
RLYB has an Altman-Z score of -3.88. This is a bad value and indicates that RLYB is not financially healthy and even has some risk of bankruptcy.
RLYB has a Altman-Z score of -3.88. This is comparable to the rest of the industry: RLYB outperforms 43.19% of its industry peers.
RLYB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -3.88 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
RLYB has a Current Ratio of 9.55. This indicates that RLYB is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of RLYB (9.55) is better than 79.65% of its industry peers.
A Quick Ratio of 9.55 indicates that RLYB has no problem at all paying its short term obligations.
RLYB has a better Quick ratio (9.55) than 79.82% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 9.55 | ||
| Quick Ratio | 9.55 |
3. Growth
3.1 Past
RLYB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 11.11%, which is quite good.
EPS 1Y (TTM)11.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.22%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
The Earnings Per Share is expected to grow by 1.44% on average over the next years.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y24.61%
EPS Next 2Y20.18%
EPS Next 3Y16.58%
EPS Next 5Y1.44%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for RLYB. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RLYB. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as RLYB's earnings are expected to grow with 16.58% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.18%
EPS Next 3Y16.58%
5. Dividend
5.1 Amount
RLYB does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
RALLYBIO CORP
NASDAQ:RLYB (12/20/2024, 8:00:01 PM)
After market: 0.9699 +0.02 (+2.09%)0.95
-0.03 (-2.68%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners75.39%
Inst Owner Change-3.35%
Ins Owners3.01%
Ins Owner Change0%
Market Cap39.42M
Analysts81.82
Price Target8.67 (812.63%)
Short Float %0.96%
Short Ratio4.04
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)15.34%
Min EPS beat(2)3.01%
Max EPS beat(2)27.67%
EPS beat(4)3
Avg EPS beat(4)6.1%
Min EPS beat(4)-9.05%
Max EPS beat(4)27.67%
EPS beat(8)7
Avg EPS beat(8)10.1%
EPS beat(12)8
Avg EPS beat(12)5.74%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-19.05%
PT rev (3m)-19.05%
EPS NQ rev (1m)10.3%
EPS NQ rev (3m)12.06%
EPS NY rev (1m)10.97%
EPS NY rev (3m)10.97%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)233.68%
Revenue NY rev (3m)233.68%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 65.91 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.56 | ||
| P/tB | 0.56 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.6
EYN/A
EPS(NY)-1.02
Fwd EYN/A
FCF(TTM)-1.23
FCFYN/A
OCF(TTM)-1.23
OCFYN/A
SpS0.01
BVpS1.71
TBVpS1.71
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -84.77% | ||
| ROE | -94.57% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-42.41%
ROA(5y)-45.43%
ROE(3y)-45.45%
ROE(5y)-51.94%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 9.55 | ||
| Quick Ratio | 9.55 | ||
| Altman-Z | -3.88 |
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)112.47%
Cap/Depr(5y)240.82%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)11.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.22%
EPS Next Y24.61%
EPS Next 2Y20.18%
EPS Next 3Y16.58%
EPS Next 5Y1.44%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y6.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year16.32%
EBIT Next 3Y12.42%
EBIT Next 5YN/A
FCF growth 1Y1.93%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y1.61%
OCF growth 3YN/A
OCF growth 5YN/A